SCHEMBL7224347

SCHEMBL7224347

COC(=O)c1cccc(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
PLAU P00749 4/20 0.62
BCL2 P10415 1/20 0.59
EGFR P00533 1/20 0.59
ERN1 O75460 1/20 0.58
KMO O15229 1/20 0.58
RXRA P19793 4/20 0.56
RXRB P28702 4/20 0.56
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
GABRG2 P18507 1/20 0.56
GABRB3 P28472 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA3 P34903 1/20 0.56
PLAT P00750 2/20 0.55
PLG P00747 1/20 0.55
RXRG P48443 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5944327 0.93 EGFR (0.63) CA12CA1CA2CA9PLAU
SCHEMBL3032014 0.91 KMO (0.63) CA12CA1CA2CA9PLAU
SCHEMBL68931 0.91 CA12 (0.69) CA12CA1CA2CA9PLAU
SCHEMBL29410906 0.90 TSHR (0.67) CA12CA1CA2CA9PLAU
SCHEMBL1221576 0.90 TSHR (0.67) CA12CA1CA2CA9PLAU
SCHEMBL27715902 0.89 CA12 (0.71) CA12CA1CA2CA9PLAU
SCHEMBL3359577 0.88 CA12 (0.65) CA12CA1CA2CA9PLAU
Hydrochloric Acid SCHEMBL29506745 0.88 CA12 (0.65) CA12CA1CA2CA9PLAU
Terephthalic Acid SCHEMBL27796382 0.88 TSHR (0.63) CA12CA1CA2CA9GAA
Terephthalic Acid SCHEMBL27517516 0.88 TSHR (0.63) CA12CA1CA2CA9GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 CA12 1304/4885CA1 1035/4885CA2 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.